According to a copy of Germany’s national vaccine strategy, the country does not expect a COVID-19 vaccine to be available before the first quarter of 2021, as reported in This is Money.
The paper from the health ministry outlines seven potential vaccines which are expected to complete testing this year or next and could be available in sufficient quantities to begin a nationwide vaccination campaign for priority groups. These include vaccines from AstraZeneca, BioNTech and partner Pfizer, Moderna, Novavax, Johnson & Johnson, GlaxoSmithKline and CureVac.
Germany plans to set up centralised vaccination centres for priority groups in the first instance.
The paper says it expects vaccines to be delivered to distribution centres in multi-dose vials without the syringes and cannulas as well as the required solvent needed for vaccination. It has asked the states to procure these accessories.
The country will collect non-personal data including age, sex, place of residence, vaccination date, vaccine product and vaccination dose administered to get an overview of the effectiveness of the vaccines, the paper says.
To read more NewsPoints articles, click here.